Duchenne muscular dystrophy trials in Spain

In Spain 15 Also abroad 97

14 of 15 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 15 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Phase 3 Study to Evaluate the Safety and Efficacy of AOC 1044 (Also Referred to as Delpacibart Zotadirsen) in Participants With DMD With Gene Mutations Amenable to Exon 44 Skipping
Where
Barcelona, Madrid, Seville
Age
7 years to 16 years
People
70 worldwide
Run by
Avidity Biosciences, Inc.
See details and how to joinNCT07587242
Phase 3Taking people
Study in which all the patients take the same investigational drug with the aim of evaluate the long-term safety, tolerability, and efficacy of GIVINOSTAT in all the patients affected with Duchenne Muscolar Dystrophy who have been already treated in one of the GIVINOSTAT studies in the past
Where
Barcelona, Esplugues de Llobregat, Sevilla, Valencia
Age
Up to 64 years
People
207 worldwide
Run by
Italfarmaco S.p.A.
See details and how to join2023-504520-26-00
Phase 2/3Taking people
A Clinical Study to Assess Safety, Efficacy and Pharmacodynamic Profile of GNT0004 in Duchenne Muscular Dystrophy
Where
Esplugues de Llobregat, Valencia
Age
6 years to 10 years
People
77 worldwide
Run by
Genethon
See details and how to joinNCT07856329 · EU 2023-505187-11-00
Phase 3Taking people
A Study of SGT-003 Gene Therapy in Ambulant Males With Duchenne Muscular Dystrophy (IMPACT DUCHENNE)
Where
Barcelona, Esplugues de Llobregat, Valencia
Age
7 years to 11 years
People
80 worldwide
Run by
Solid Biosciences Inc.
See details and how to joinNCT07160634 · EU 2025-522949-22-00
Phase 2Enrolling by invitation
Open-Label Extension of EDG-5506 in Participants With Becker Muscular Dystrophy
Where
Barcelona, Donostia / San Sebastian, Valencia
People
260 worldwide
Run by
Edgewise Therapeutics, Inc.
See details and how to joinNCT06066580
Phase 1/2Taking people
A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping to Evaluate the Safety and Efficacy of ENTR-601-44
Where
Barcelona, Esplugues de Llobregat
Age
4 years to 20 years
People
24 worldwide
Run by
Entrada Therapeutics, Inc.
See details and how to joinNCT07037862 · EU 2024-517584-23-00
Phase 1/2Taking people
A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping to Evaluate the Safety and Efficacy of ENTR-601-45
Where
Barcelona, Esplugues de Llobregat
Age
4 years to 20 years
People
24 worldwide
Run by
Entrada Therapeutics, Inc.
See details and how to joinNCT07038824 · EU 2024-517499-39-00
Phase 3Taking people
Efficacy, Safety and Tolerability of Givinostat in Non-ambulant Patients With Duchenne Muscular Dystrophy
Where
Esplugues de Llobregat, Valencia
Age
9 years to 17 years
People
138 worldwide
Run by
Italfarmaco
See details and how to joinNCT05933057 · EU 2023-503521-19-00
Phase 2Taking people
An Open-Label Extension Study to Evaluate the Long-term Safety and Efficacy of BMN 351 in Participants With Duchenne Muscular Dystrophy
Where
Sevilla
Age
4 years to 64 years
People
18 worldwide
Run by
BioMarin Pharmaceutical
See details and how to joinNCT07573631 · EU 2024-511656-41-00
Phase 2Taking people
Long-Term Extension Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon Skipping to Evaluate the Safety and Efficacy of Endosomal Escape Vehicle Phosphorodiamidate Morpholino Oligomer Platform Products (ELEVATE-LTE)
Where
Barcelona, Esplugues de Llobregat
Age
4 years to 20 years
People
80 worldwide
Run by
Entrada Therapeutics, Inc.
See details and how to joinNCT07682129 · EU 2025-525124-10-00
Phase 3Taking people
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Global Study with an Open-Label Extension to Evaluate the Efficacy and Safety of Intravenous AOC 1044 (delpacibart zotadirsen) for the Treatment of DMD with Gene Mutations Amenable to Exon 44 Skipping
Where
Esplugues de Llobregat, Madrid, Sevilla
Age
Up to 17 years
People
42 worldwide
Run by
Avidity Biosciences Inc.
See details and how to join2025-523087-20-00
Phase 3Taking people
A Long-term Follow-up Study of Participants Who Received Delandistrogene Moxeparvovec (SRP-9001) in a Previous Clinical Study
Where
Esplugues De Llobregat, Valencia
Age
Up to 64 years
People
400 worldwide
Run by
Sarepta Therapeutics, Inc.
See details and how to joinNCT05967351 · EU 2023-505043-39-00
Phase 2/3Taking people
Givinostat in Duchenne's Muscular Dystrophy Long-term Safety and Tolerability Study
Where
Barcelona, Esplugues de Llobregat, Seville, Valencia
Age
7 years and over
People
206 worldwide
Run by
Italfarmaco
See details and how to joinNCT03373968
No phaseEnrolling by invitation
Effectiveness of 5-week Digital Respiratory Practice in Children With Duchenne and Becker Muscular Dystrophies.
Where
Málaga
Age
5 years to 20 years
People
12
Run by
University of Malaga
See details and how to joinNCT06363526